1. GRAIL Press release . GRAIL and UK government to make galleri multi-cancer early detection blood test available to patients. November 26, 2020. https://grail.com/press-releases/grail-and-uk-government-to-make-galleri-multi-cancer-early-detection-blood-test-available-to-patients/ (accessed 8 October 2020).
Google Scholar2. Kumar, H . Rapid response to: “liquid biopsy” for cancer screening. Br Med J 2021; 372: m4933.
Google Scholar | Medline3. Carr, D, Welch, HG. Editor’s note: this opinion piece is now outdated. STAT. First Opinion, February 12, 2021. https://www.statnews.com/2021/02/12/nhs-need-control-arm-grails-cancer-test/
Google Scholar4. NHS-Galleri Trial. https://www.nhs-galleri.org/. Accessed 10/9/2021.
Google Scholar5. Old, R, Pharoah, P, Wald, N. NHS Announces a pilot of a blood test for early detection of many cancer. J Med Screen 2021; 28: 1–2.
Google Scholar | SAGE Journals | ISI6. GRAIL announces first healthcare system to offer Galleri, novel multi-cancer early detection blood test. Businesswire.com. March 2, 2021. https://www.businesswire.com/news/home/20210302005700/en/GRAIL-Announces-First-Health-System-to-Offer-Galleri-Novel-Multi-Cancer-Early-Detection-Blood-Test
Google Scholar7. Alpert, B . Blood tests that Can detect cancers are nearly here. If You want One, you’ll have to Pay Up. Barron’s. April 8, 2021. https://www.barrons.com/articles/want-a-liquid-biopsy-cancer-test-pay-up-or-be-patient-51617878700
Google Scholar8. Fleming, TR, DeMets, DL. Surrogate End points in clinical trials: are We being misled? Ann Intern Med 1996; 125: 605–613.
Google Scholar | Crossref | Medline | ISI9. Prasad, V, Kim, C, Burotto, M. The strength of association between surrogate end points and survival in oncology – a systemic review of trial-level meta-analyses. JAMA Intern Med 2015; 175: 1389–1398.
Google Scholar | Crossref | Medline | ISI10. Wilson, JMG, Junger, G. Principles and practice of screening for disease. Geneva: World Health Organization, 1968. Accessed online: http://apps.who.int/iris/bitstream/handle/10665/37650/WHO_PHP_34.pdf?sequence=17
Google Scholar11. Prasad, V . Powering cancer screening for overall mortality. Ecancermedicalscience 2013; v.7: ed27.
Google Scholar12. Klein, EA , et al. Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set. Ann Oncol 2021; 32: 1167–1177. https://doi.org/10.1016/j.annonc.2021.05.806
Google Scholar13. Black, WC, Haggstrom, DA, Welch, HG. All-cause mortality in randomized trials of cancer screening. J Natl Cancer Inst 2002; 94: 167–173.
Google Scholar | Crossref | Medline14. Screening Saves Lives. Run by the Middlesbrough Council. https://screeningsaveslives.co.uk/
Google Scholar15. Singer, N . In Push for Cancer Screening, Limited Benefits. The New York Times [Internet]. 16 July 2000. https://www.nytimes.com/2009/07/17/health/17screening.html
Google Scholar16. Schwartz, LM, Woloshin, S, Fowler, FJ, et al. Enthusiasm for cancer screening in the United States. JAMA 2004; 291: 71–78.
Google Scholar | Crossref | Medline | ISI17. Saquib, N, Saquib, J, Ioannidis, JP. Does screening for disease save lives in asymptomatic adults? Systematic review of meta-analyses and randomized trials. Int J Epidemiol 2015; 44: 264–277.
Google Scholar | Crossref | Medline18. Mortality statistics – underlying cause and age. England 2019. Office for National Statistics. https://www.nomisweb.co.uk/datasets/mortsa
Google Scholar19. Hubbell, E, Clarke, CA, Aravanis, AM, et al. Modeled reductions in late-stage cancer with a multi-cancer early detection test. Cancer Epidemiol Biomarkers Prev 2021; 30: 460–468.
Google Scholar | Crossref | Medline20. Pereira, TV, Horwitz, RI, Ioannidis, JPA. Empirical evaluation of very large treatment effects of medical interventions. JAMA 2012; 208: 1676–1684.
Google Scholar | Crossref21. Mills, EJ, Rachlis, B, Wu, P, et al. Primary prevention of cardiovascular mortality and events with statin treatments: a network meta-analysis involving more than 65,000 patients. J Am Coll Cardiol 2008; 52: 1769–1781.
Google Scholar | Crossref | Medline | ISI22. DeGregori, J, Pharoah, P, Sasieni, P, et al. Cancer screening, surrogates of survival, and the soma. Cancer Cell 2020; 38: 433–437.
Google Scholar | Crossref | Medline23. Neumann, PJ, Cohen, JT, Hammitt, JK, et al. Willingness-to-pay for predictive tests with no immediate treatment implications: a survey of US residents. Health Econ 2021; 21; 238–251.
Google Scholar | Crossref24. https://touchoncology.com/diagnostics-and-screening/journal-articles/criteria-for-evaluating-multi-cancer-early-detection-tests/
Google Scholar25. Welch, HG, Mogielnicki, J. Presumed benefit: lessons from the American experience with marrow transplantation for breast cancer. Br Med J 2002; 324: 1088–1092.
Google Scholar | Crossref | Medline26. Herrera-Perez, D, Haslam, A, Crain, T, et al. A comprehensive review of randomized clinical trials in three medical journals reveals 396 medical reversals. Elife 2019; 8: e45183.
Google Scholar | Crossref | Medline27. Haslam, A, Gill, J, Crain, T, et al. The frequency of medical reversals in a cross-sectional analysis of high-impact oncology journals, 2009–2018. BMC Cancer 2021; 21: 889.
Google Scholar | Crossref | Medline